Tercica, Inc., was a biopharmaceutical company based in

Brisbane, California Brisbane (pron. , unlike Brisbane, Queensland, Australia) is a small city located in California in the northern part of San Mateo County, California, San Mateo County on the lower slopes of San Bruno Mountain. It is located on the southern bor ...

, United States. It developed

Increlex Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure ...

(mecasermin DNA origininjection), also known as recombinant human Insulin-like Growth Factor-1 ( rhIGF-1). Tercica applied to the

Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ...

(FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency (

Primary IGFD Primary or primaries may refer to: Arts, entertainment, and media Music Groups and labels * Primary (band), from Australia * Primary (musician), hip hop musician and record producer from South Korea * Primary Music, Israeli record label Works * ...

), which is characterized by growth failure, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. Tercica licensed rights to develop, manufacture, and market Increlex from

Genentech Genentech, Inc., is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within ...

, Inc. Increlex conducted Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with

. In 2007, a case between Insmed and Tercica was settled when the jury found that Insmed infringed patents licensed to Tercica for Increlex. In the settlement, Insmed agreed to stop selling Iplex in the United States as a treatment for growth deficiencies and to withdraw an application to have the drug approved for such use in Europe. In 2008, the

Ipsen Group Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world’s top 15 biopharmaceutical com ...

acquired Tercica and changed its name to Ipsen Biopharmaceuticals, Inc.

References

External links

Ipsen Biopharmaceuticals
website Companies formerly listed on the Nasdaq Biotechnology companies of the United States Companies based in San Mateo County, California Brisbane, California {{med-company-stub

See also

References

External links